Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow
NCT ID: NCT06106997
Last Updated: 2023-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
54 participants
INTERVENTIONAL
2024-01-31
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Is an MRI-only workflow based on deep learning sCTs feasible in clinical routine? Participants will be treated as in clinical routine, but treatment planning will be based on sCTs, that are generated from MRI images. The dosimetrical equivalence to the standard CT based workflow will be tested at several points in the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of the MRI Restraint System on the Quality of the Synthetic Scan for Intracranial Radiotherapy Treatment
NCT06994702
Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases
NCT02265549
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
NCT05576103
Response Assessment During MR-guided Radiation Therapy for Glioblastoma
NCT05565326
Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases
NCT06405256
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 54 patients with an indication for radiation treatment of the brain and stereotactic mask immobilization will be recruited. All study patients will receive standard therapy and imaging including both CT and MRI. All patients will receive dedicated RT-MRI scans in treatment position. An sCT will be reconstructed from an acquired MRI DIXON-sequence using a commercially available deep learning solution on which subsequent radiotherapy planning will be performed. Through multiple quality assurance (QA) measures and reviews during the course of the study, the feasibility of an MRI-only workflow and comparative parameters between sCT and standard CT workflow will be investigated holistically. These QA measures include feasibility and quality of image guidance (IGRT) at the linear accelerator using sCT derived digitally reconstructed radiographs in addition to potential dosimetric deviations between the CT and sCT plan. The aim of this clinical study is to establish a brain MRI-only workflow as well as to identify risks and QA mechanisms to ensure a safe integration of deep learning-based sCT into radiotherapy planning and delivery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sCT workflow
sCT workflow
brain radiotherapy
brain radiotherapy planned on synthetic CTs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
brain radiotherapy
brain radiotherapy planned on synthetic CTs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient older than 18 years
* Tumor or metastases in the brain
* Immobilization with stereotactic mask
* Treatment on stereotactic linear accelerator (2.5 mm leafs) equipped with 2D/2D X-ray system
Exclusion Criteria
* Metal implants, pacemakers or other patient-specific factors associated with increased risk from an MRI scan
* Renal insufficiency (eGFR \< 60 ml/min), allergy or other patient-specific factors that constitute a contraindication to contrast administration
* Renal insufficiency (eGFR \< 60 ml/min), allergy or other patient-specific factors associated with an increased risk from contrast administration
* Patients who are institutionalized in care facilities, prisons or other supervised facilities.
* Patients under guardianship
* Non-consenting patients
* Pregnant or breastfeeding patients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Erlangen-Nürnberg Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christoph Bert, Prof. Dr. rer. nat
Role: PRINCIPAL_INVESTIGATOR
Universitätsklinikum Erlangen, Strahlenklinik
Florian Putz, PD Dr. med.
Role: PRINCIPAL_INVESTIGATOR
Universitätsklinikum Erlangen, Strahlenklinik
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erlangen, Universitätsklinikum Strahlenklinik
Erlangen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Grigo J, Szkitsak J, Hofler D, Fietkau R, Putz F, Bert C. "sCT-Feasibility" - a feasibility study for deep learning-based MRI-only brain radiotherapy. Radiat Oncol. 2024 Mar 8;19(1):33. doi: 10.1186/s13014-024-02428-3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
sCT-Feasibility
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.